MDVL / MedAvail Holdings, Inc. - Документы SEC, Годовой отчет, Доверенное заявление

MDVL / MedAvail Holdings, Inc. / Alyeska Investment Group, L.P. Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2024 MedAvail Holding

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2024 MedAvail Holdings, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-36533 (Commission File No.)

US58406B2025 / MEDAVAIL HOLDINGS INC / Redmile Group, LLC - SC 13D/A Activist Investment

SC 13D/A 1 tm245380d1sc13da.htm SC 13D/A UNITED STATES SECURITIES & EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 7)* MedAvail Holdings, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 58406B202 (CUSIP Number) Redmile Group, LLC Attn: Jennifer Ciresi One Letterman Drive, Bldg D, Ste D3-

February 2, 2024

Exhibit 16.1 February 2, 2024 Securities and Exchange Commission Washington, D.C. 20549 Commissioners: We have read MedAvail Holdings, Inc.’s statements included under Item 4.01(a) of its Form 8-K filed on February 2, 2024 and we agree with such statements concerning our firm. /s/ SingerLewak LLP 10960 Wilshire Blvd, Suite 1100 Los Angeles California 90024 | T: 310.477.3924 | F: 310.478.6070

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 1, 2024 MedAvail Holding

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 1, 2024 MedAvail Holdings, Inc. (Exact name of Registrant as specified in its charter) Delaware 001-36533 90-0772394 (State or other jurisdiction of incorporation or organiza

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2024 MEDAVAIL HOLDING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2024 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36533 90-0772394 (State or other jurisdiction of incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2023 MEDAVAIL HOLDIN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2023 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36533 90-0772394 (State or other jurisdiction of incorporation) (Commissi

MedAvail Receives Nasdaq Notification of Non-Compliance Related to Delayed Quarterly Report on Form 10-Q

Exhibit 99.1 MedAvail Receives Nasdaq Notification of Non-Compliance Related to Delayed Quarterly Report on Form 10-Q PHOENIX, Ariz. GlobeNewswire – November 17, 2023 – MedAvail Holdings, Inc. (Nasdaq: MDVL) (“MedAvail” or the “Company”), an innovative pharmacy technology company, announced today that on November 16, 2023, the Company received a delinquency notification letter from the Listing Qua

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB Number: SEC File Number: CUSIP: 58406B103 (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: September 30, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Trans

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 MEDAVAIL HOLDIN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36533 90-0772394 (State or other jurisdiction of incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2023 MEDAVAIL HOLDINGS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2023 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36533 90-0772394 (State or other jurisdiction of incorporation) (Commission

MedAvail Reports Second Quarter 2023 Financial Results

Exhibit 99.1 MedAvail Reports Second Quarter 2023 Financial Results PHOENIX, Ariz. GlobeNewswire – August 14, 2023 – MedAvail Holdings, Inc. (Nasdaq: MDVL) (“MedAvail”), an innovative pharmacy technology company, today reported financial results for the second quarter ended June 30, 2023. “During the second quarter, we were able to sustain the positive momentum that we have experienced since we be

Q2 2023 Letter to Stockholders August 14, 2023 Page 1 of 9 Legal Disclaimer Certain statements included in these prepared remarks that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the Privat

Q2 2023 Letter to Stockholders August 14, 2023 Page 1 of 9 Legal Disclaimer Certain statements included in these prepared remarks that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36533 MEDAVAIL HO

Transforming Today’s Pharmacy Investor Presentation I August 2023 NASDAQ: MDVL 2 Forward Looking Statement MedAvail Holdings, Inc. (“MedAvail”) cautions you that the statements in this presentation that are not a description of historical fact are fo

ex993erpresentationq223 Transforming Today’s Pharmacy Investor Presentation I August 2023 NASDAQ: MDVL 2 Forward Looking Statement MedAvail Holdings, Inc.

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36533 90-0772394 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2023 MEDAVAIL HOLDINGS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2023 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36533 90-0772394 (State or other jurisdiction of incorporation) (Commission F

Certificate of Amendment of Amended and Restated Certificate of Incorporation of MedAvail Holdings, Inc.

Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF MEDAVAIL HOLDINGS, INC. MedAvail Holdings, Inc., a Delaware corporation (the “Corporation”), hereby certifies as follows: 1. The name of the Corporation is MedAvail Holdings, Inc., and the original Certificate of Incorporation of the Corporation was filed with the Secretary of State of Delaware under the n

MedAvail Announces 1-for-50 Reverse Stock Split

Exhibit 99.1 MedAvail Announces 1-for-50 Reverse Stock Split PHOENIX, Ariz., July 31, 2023 /GlobeNewswire/ – MedAvail Holdings, Inc. (Nasdaq: MDVL) (“MedAvail” or the “Company”), an innovative pharmacy technology company, announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-50. The reverse stock split will become effective at 5:00 p.m.

MEDAVAIL HOLDINGS, INC. 4720 East Cotton Gin Loop, Suite 220, Phoenix, Arizona 85040

MEDAVAIL HOLDINGS, INC. 4720 East Cotton Gin Loop, Suite 220, Phoenix, Arizona 85040 July 18, 2023 VIA EDGAR Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Kate Beukenkamp Re: MedAvail Holdings, Inc. Acceleration Request for Registration Statement on Form S-3 File No. 333-273032 Dear Ms. Beukenkamp: Pursuant to Rule

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MedAvail Holdings, Inc. (Exact name of registrant as specified in its charter)

As filed with the Securities and Exchange Commission on July 14, 2023 Registration No.

As filed with the Securities and Exchange Commission on June 29, 2023

As filed with the Securities and Exchange Commission on June 29, 2023 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MedAvail Holdings, Inc. (Exact name of registrant as specified in its charter)

As filed with the Securities and Exchange Commission on June 29, 2023 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) MedAvail Holdings, Inc.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2023 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36533 90-0772394 (State or other jurisdiction of incorporation or organizatio

Explanatory Note

Exhibit 99.1 Explanatory Note MedAvail Holdings, Inc. (“we”, “our”, or the “Company”) is filing this Exhibit 99.1 to our Current Report on Form 8-K to present the financial results of our former Retail Pharmacy Services business (“pharmacy services business”) as a discontinued operation for the years ended December 31, 2022 and 2021, and to reflect the disclosure of our Pharmacy Technology Service

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) MedAvail Holdings, Inc.

MDVL / MedAvail Holdings Inc / Redmile Group, LLC - SC 13D/A Activist Investment

UNITED STATES SECURITIES & EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* MedAvail Holdings, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 58406B103 (CUSIP Number) Redmile Group, LLC Attn: Jennifer Ciresi One Letterman Drive, Bldg D, Ste D3-300 San Francisco, CA 94129 (415) 489-998

MDVL / MedAvail Holdings Inc / Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. - SC 13D/A Activist Investment

SC 13D/A 1 d236269dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* MedAvail Holdings, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 58406B103 (CUSIP Number) Fan Yu Unit 3002-3004, 30th Floor Gloucester Tower, The Landmark 15 Queen’s Road Centra

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 MEDAVAIL HOLDINGS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36533 90-0772394 (State or other jurisdiction of incorporation or organizatio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Prox

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2023 MEDAVAIL HOLDINGS, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2023 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36533 90-0772394 (State or other jurisdiction of incorporation) (Commission Fi

MedAvail Holdings, Inc. Investor Presentation

Exhibit 99.2 Exhibit 99.2 Exhibit 99.2 Exhibit 99.2 Exhibit 99.2 Exhibit 99.2 Exhibit 99.2 Exhibit 99.2 Exhibit 99.2 Exhibit 99.2 Exhibit 99.2 Exhibit 99.2 Exhibit 99.2 Exhibit 99.2 Exhibit 99.2 Exhibit 99.2 Exhibit 99.2 Exhibit 99.2 Exhibit 99.2 Exhibit 99.2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36533 MEDAVAIL H

MedAvail Reports First Quarter 2023 Financial Results

Exhibit 99.1 MedAvail Reports First Quarter 2023 Financial Results PHOENIX, Ariz. GlobeNewswire – May 18, 2023 – MedAvail Holdings, Inc. (Nasdaq: MDVL) (“MedAvail”), an innovative pharmacy technology company, today reported financial results for the first quarter ended March 31, 2023. “During the first quarter, we made good progress toward our mission of becoming a leader in the development and ma

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB Number: SEC File Number: CUSIP: 58406B103 (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: March 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transitio

Letter to the Securities and Exchange Commission from Baker Tilly US, LLP, dated May 8, 2023

Exhibit 16.1 May 8, 2023 Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Dear Ladies and Gentlemen: We are the independent registered public accounting firm for MedAvail Holdings, Inc. (the “Company”). We have read the Company’s disclosure set forth in Item 4.01 “Changes in Registrant’s Certifying Accountant” of the Company’s Current Report on Form 8-K dated May 8, 2023 (t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2023 MEDAVAIL HOLDINGS, IN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2023 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36533 90-0772394 (State or other jurisdiction of incorporation or organization)

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2023 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36533 90-0772394 (State or other jurisdiction of incorporation or organization)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a6(e)(2)) ☒ Definitive Proxy Statem

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2023 MEDAVAIL HOLDINGS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2023 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36533 90-0772394 (State or other jurisdiction of incorporation or organizati

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a6(e)(2)) ☐ Definitive Proxy Statem

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2023 MEDAVAIL HOLDINGS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2023 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36533 90-0772394 (State or other jurisdiction of incorporation or organizati

Asset Purchase and Sale Agreement dated January 20, 2023

ASSET PURCHASE AND SALE AGREEMENT THIS ASSET PURCHASE AND SALE AGREEMENT (hereinafter, this “Agreement”) is dated as of January 20, 2023, by and between MedAvail Pharmacy, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36533 MEDAVAIL HOLDINGS, INC. (Exac

Change in CEO Base Salary

Exhibit 10.23 PRIVATE AND CONFIDENTIAL April 6, 2023 Via email Mark Doerr Re: Change in Base Salary Dear Mark, Based on MedAvail’s reduction in revenue, EBITDA and workforce size for the Technology Only business, your annual base salary will be reduced from $450,000 to $400,000 at your request. This reduction in salary will go into effect on April 14, 2023 through February 1, 2024, at which time y

McKesson Supply Agreement

MedAvail Holdings, Inc. Investor Presentation

Exhibit 99.2 Exhibit 99.2 Exhibit 99.2 Exhibit 99.2 Exhibit 99.2 Exhibit 99.2 Exhibit 99.2 Exhibit 99.2 Exhibit 99.2 Exhibit 99.2 Exhibit 99.2 Exhibit 99.2 Exhibit 99.2 Exhibit 99.2 Exhibit 99.2 Exhibit 99.2 Exhibit 99.2 Exhibit 99.2 Exhibit 99.2 Exhibit 99.2

MedAvail Reports Fourth Quarter and Full-Year 2022 Financial Results

Exhibit 99.1 MedAvail Reports Fourth Quarter and Full-Year 2022 Financial Results PHOENIX, Ariz. GlobeNewswire – April 13, 2023 – MedAvail Holdings, Inc. (Nasdaq: MDVL) (“MedAvail”), an innovative pharmacy technology company, today reported financial results for the three months and full-year ended December 31, 2022. “Since assuming the role of CEO in January 2022, I have been impressed by the man

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2023 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36533 90-0772394 (State or other jurisdiction of incorporation) (Commission

MedAvail Holdings, Inc. Summary of Unaudited Pro Forma Condensed Consolidated Financial Information (Dollars in thousands, except share and per share data)

Exhibit 99.1 MedAvail Holdings, Inc. Summary of Unaudited Pro Forma Condensed Consolidated Financial Information (Dollars in thousands, except share and per share data) Overview On January 18, 2023, MedAvail Holdings, Inc., a Delaware corporation (the “Company”), announced its plan to exit its pharmacy services business (the “Pharmacy Services Business”) to focus on the Company’s pharmacy technolo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2023 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36533 90-0772394 (State or other jurisdiction of incor

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2023 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36533 90-0772394 (State or other jurisdiction of incorporation or organizati

Letter Agreement dated March 29, 2023

Exhibit 10.1 March 29, 2023 Letter Agreement Reference is made to the Loan and Security Agreement dated as of June 7, 2021 by and among (a) SILICON VALLEY BANK, A DIVISION OF FIRST-CITIZENS BANK & TRUST COMPANY (SUCCESSOR BY PURCHASE TO THE FEDERAL DEPOSIT INSURANCE CORPORATION AS RECEIVER FOR SILICON VALLEY BRIDGE BANK, N.A. (AS SUCCESSOR TO SILICON VALLEY BANK)) (“SVB”), in its capacity as admin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB Number: SEC File Number: CUSIP: 58406B103 (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transi

MDVL / MedAvail Holdings Inc / Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* MedAvail Holdings, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 58406B103 (CUSIP Number) Fan Yu Unit 3002-3004, 30th Floor Gloucester Tower, The Landmark 15 Queen’s Road Central Hong Kong +852 31219699 (Nam

MDVL / MedAvail Holdings Inc / Redmile Group, LLC - SC 13D/A Activist Investment

UNITED STATES SECURITIES & EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* MedAvail Holdings, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 58406B103 (CUSIP Number) Redmile Group, LLC Attn: Jennifer Ciresi One Letterman Drive, Bldg D, Ste D3-300 San Francisco, CA 94129 (415) 489-998

Joint Filing Agreement

Exhibit 99.9 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including any and all amendments thereto, the “Schedule 13D”) relating to the common stock, $0.001 par value per share, of MedAvail Holdings, Inc

Form of Pre-Funded Warrant to Purchase Common Stock

Exhibit 10.3 THE OFFER AND SALE OF THESE SECURITIES AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED, ASSIGNED OR OTHERWISE DISPOSED OF (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION ST

Form of Series A Warrant to Purchase Common Stock

Exhibit 10.4 THE OFFER AND SALE OF THESE SECURITIES AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED, ASSIGNED OR OTHERWISE DISPOSED OF (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION ST

Registration Rights Agreement, dated as of March 9, 2023

Exhibit 10.2 Execution Copy REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into effective as of March 9, 2023, by and between MedAvail Holdings, Inc., a Delaware corporation (the “Company”) and each “Purchaser” named in the Purchase Agreement (as defined below) (collectively, the “Purchasers”). Capitalized terms used herein shall have the me

MedAvail Announces Closing of $16 Million Private Placement

Exhibit 99.1 MedAvail Announces Closing of $16 Million Private Placement PHOENIX, March 14, 2023 (GLOBE NEWSWIRE) - MedAvail Holdings, Inc. (Nasdaq: MDVL) (“MedAvail”), an innovative pharmacy technology company, today announced that on March 13, 2023, it closed a private placement (the “Offering”) of securities with certain institutional investors pursuant to the terms of a definitive securities p

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2023 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36533 90-0772394 (State or other jurisdiction of incorporation or organizatio

Securities Purchase Agreement, dated as of March 9, 2023

Exhibit 10.1 Execution Copy SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is made and entered into as of March 9, 2023 (the “Effective Date”) by and among MedAvail Holdings, Inc., a Delaware corporation (the “Company”), and the purchasers listed on the signature pages hereto (each a “Purchaser” and together the “Purchasers”). Certain terms used and not otherwi

Warrant to Purchase Stock dated February 10, 2023 issued to Silicon Valley Bank

Exhibit 10.2 Execution Version THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 6.3 AND 6.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL

Warrant to Purchase Stock dated February 10, 2023 issued to SVB Innovation Credit Fund VIII, L.P.

Exhibit 10.3 Execution Version THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 6.3 AND 6.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL

First Amendment, Consent and Default Waiver to Loan and Security Agreement dated February 10, 2023, by and among MedAvail Holdings, Inc., MedAvail Pharmacy, Inc., MedAvail, Inc., MedAvail Technologies (US) Inc., MedAvail Technologies, Inc., Silicon Valley Bank, and SVB Innovation Credit Fund VIII, L.P.

Exhibit 10.1 FIRST AMENDMENT, CONSENT AND DEFAULT WAIVER TO LOAN AND SECURITY AGREEMENT This FIRST AMENDMENT, CONSENT AND DEFAULT WAIVER to Loan and Security Agreement (this “Agreement”) is entered into as of February 10, 2023, by and between (a) SILICON VALLEY BANK, a California corporation, and an authorized foreign bank under the Bank Act (Canada) (“SVB”), in its capacity as administrative agen

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2023 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36533 90-0772394 (State or other jurisdiction of incorporation or organiz

MDVL / Medavail Holdings Inc / Alyeska Investment Group, L.P. Passive Investment

SC 13G 1 alyeska-mdvl123122.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* MEDAVAIL HOLDINGS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 58406B103 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the app

Separation Agreement and Release by and between MedAvail Holdings, Inc. and Matt Broome

Exhibit 10.2 SEPARATION AGREEMENT AND RELEASE This Separation Agreement and Release (“Agreement”) is made and entered into by and between Matthew Broome (“Employee”) and MedAvail Technologies (US) Inc., acting on behalf of itself and its parents, affiliates, subsidiaries, and related companies, including, without limitation, MedAvail Holdings, Inc., MedAvail, Inc., MedAvail Pharmacy, Inc. and MedA

Separation Agreement and Release by and between MedAvail Holdings, Inc. and Steven Hess

Exhibit 10.1 SEPARATION AGREEMENT AND RELEASE This Separation Agreement and Release (“Agreement”) is made and entered into by and between Steven Hess (“Employee”) and MedAvail Technologies (US) Inc., acting on behalf of itself and its parents, affiliates, subsidiaries, and related companies, including, without limitation, MedAvail Holdings, Inc., MedAvail, Inc., MedAvail Pharmacy, Inc. and MedAvai

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2023 MEDAVAIL HOLDING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2023 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36533 90-0772394 (State or other jurisdiction of incorporation or organiza

MedAvail announces Sale of Pharmacy Assets to CVS Pharmacy

EX-99.1 2 pressreleasedatedjanuary26.htm EX-99.1 Exhibit 99.1 MedAvail announces Sale of Pharmacy Assets to CVS Pharmacy PHOENIX, Ariz. GlobeNewswire – January 26, 2023 – MedAvail Holdings, Inc. (Nasdaq: MDVL) (“MedAvail”), an innovative technology-enabled pharmacy company, today announced it has entered into a definitive agreement with CVS Pharmacy, Inc., on behalf of itself and its subsidiaries

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2023 MEDAVAIL HOLDING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2023 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36533 90-0772394 (State or other jurisdiction of incorporation or organiza

Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2023 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36533 90-0772394 (State or other jurisdiction of incorporation) (Commissio

MedAvail announces Strategic Restructuring of Business to Focus on Profitability Company focusing on innovative technology and exit of pharmacy services Restructuring to further extend capital resources Annual cash burn expected to be reduced by grea

Exhibit 99.1 MedAvail announces Strategic Restructuring of Business to Focus on Profitability Company focusing on innovative technology and exit of pharmacy services Restructuring to further extend capital resources Annual cash burn expected to be reduced by greater than 65% in 2023 Company exploring financing options in connection with business transition PHOENIX, Ariz. GlobeNewswire – January 19

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2022 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36533 90-0772394 (State or other jurisdiction of incorporation) (Commissi

Corporate Presentation 2 MedAvail Holdings, Inc. (“MedAvail”) cautions you that the statements in this presentation that are not a description of historical fact are forward-looking statements which may be identified by use of the words such as “anti

mdvlinvestorpresentation Corporate Presentation 2 MedAvail Holdings, Inc. (“MedAvail”) cautions you that the statements in this presentation that are not a description of historical fact are forward-looking statements which may be identified by use of the words such as “anticipate,” “believe,” “expand,” “expect,” “grow,” “intend,” “opportunity,” “plan,” “potential,” “project”, “target” and “will”

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 MEDAVAIL HOLDIN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36533 90-0772394 (State or other jurisdiction of incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36533 MEDAVA

MedAvail Reports Third Quarter 2022 Financial Results

EX-99.1 2 exhibit991-8xkq32022.htm EX-99.1 Exhibit 99.1 MedAvail Reports Third Quarter 2022 Financial Results PHOENIX, Ariz. – November 10, 2022 – MedAvail Holdings, Inc. (Nasdaq: MDVL) (“MedAvail”) a technology-enabled pharmacy company, today reported financial results for the three months ended September 30, 2022. “During the third quarter, we made significant progress on our key milestones – we

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2022 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36533 90-0772394 (State or other jurisdiction of incorporation) (Commissio

As filed with the Securities and Exchange Commission on October 14, 2022

As filed with the Securities and Exchange Commission on October 14, 2022 Registration No.

Corporate Presentation 2 MedAvail Holdings, Inc. (“MedAvail”) cautions you that the statements in this presentation that are not a description of historical fact are forward-looking statements which may be identified by use of the words such as “anti

EX-99.1 2 mdvlinvestorpresentation.htm EX-99.1 Corporate Presentation 2 MedAvail Holdings, Inc. (“MedAvail”) cautions you that the statements in this presentation that are not a description of historical fact are forward-looking statements which may be identified by use of the words such as “anticipate,” “believe,” “expand,” “expect,” “grow,” “intend,” “opportunity,” “plan,” “potential,” “project”

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2022 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36533 90-0772394 (State or other jurisdiction of incorporation) (Commission

$50,000,000 Common Stock

424B5 1 medavailatm424b5.htm 424B5 PROSPECTUS Filed Pursuant to Rule 424(b)(5) Registration No. 333-266843 $50,000,000 Common Stock We have entered into a sales agreement, or the sales agreement, with Cowen and Company, LLC, or Cowen, relating to the sale of shares of our common stock, par value $0.001 per share, offered by this prospectus and the accompanying prospectus. In accordance with the te

MedAvail Holdings, Inc. 14,117,646 Shares of Common Stock

PROSPECTUS Filed Pursuant to Rule 424(b)(3) Registration No. 333-266842 MedAvail Holdings, Inc. 14,117,646 Shares of Common Stock This prospectus relates to the disposition, from time to time, by the selling stockholders identified in this prospectus under the caption ?Selling Stockholders? on page 9 of up to 14,117,646 shares of our common stock, including shares issuable upon the exercise of war

August 24, 2022

August 24, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Janice Adeloye and Taylor Beech Re: MedAvail Holdings, Inc. Registration Statement on Form S-3 Filed August 12, 2022 File No. 333-266843 Acceleration Request Requested Date: August 26, 2022 Requested Time: 4:30 p.m. (Eastern Time) Ladies and Gentlem

August 24, 2022

CORRESP 1 filename1.htm August 24, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Janice Adeloye and Taylor Beech Re: MedAvail Holdings, Inc. Registration Statement on Form S-3 Filed August 12, 2022 File No. 333-266842 Acceleration Request Requested Date: August 26, 2022 Requested Time: 4:30 p.m. (Eastern

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36533 MEDAVAIL HO

, by and between the registrant and Cowen and Company, LLC

Exhibit 1.2 MEDAVAIL HOLDINGS, INC. $50,000,000 COMMON STOCK SALES AGREEMENT August 12, 2022 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: MedAvail Holdings, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. Issuance and Sale of Placement Shares. The Company agrees tha

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) MedAvail Holdings, Inc.

As filed with the Securities and Exchange Commission on August 12, 2022

As filed with the Securities and Exchange Commission on August 12, 2022 Registration No.

As filed with the Securities and Exchange Commission on August 12, 2022

As filed with the Securities and Exchange Commission on August 12, 2022 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) MedAvail Holdings, Inc.

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36533 90-0772394 (State or other jurisdiction of incorporation) (Commission

MedAvail Reports Second Quarter 2022 Financial Results

EX-99.1 2 exhibit991-8xkq22022.htm EX-99.1 Exhibit 99.1 MedAvail Reports Second Quarter 2022 Financial Results MISSISSAUGA, Ontario and PHOENIX, Ariz. – August 11, 2022 – MedAvail Holdings, Inc. (Nasdaq: MDVL) (“MedAvail”) a technology-enabled pharmacy company, today reported financial results for the three months ended June 30, 2022. “We continued to execute on our strategic initiatives in the se

Corporate Presentation 2 MedAvail Holdings, Inc. (“MedAvail”) cautions you that the statements in this presentation that are not a description of historical fact are forward- looking statements which may be identified by use of the words such as “ant

EX-99.2 3 mdvlinvestorxpresentati.htm EX-99.2 Corporate Presentation 2 MedAvail Holdings, Inc. (“MedAvail”) cautions you that the statements in this presentation that are not a description of historical fact are forward- looking statements which may be identified by use of the words such as “anticipate,” “believe,” “expand,” “expect,” “grow,” “intend,” “opportunity,” “plan,” “potential,” “project”

Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2022 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36533 90-0772394 (State or other jurisdiction of incorporation) (Commission Fi

Letter to the Securities and Exchange Commission from PricewaterhouseCoopers LLP, dated July 11, 2022

July 11, 2022 Securities and Exchange Commission 100 F Street, N.E. Washington DC 20549 USA Commissioners: We have read the statements made by MedAvail Holdings, Inc. (copy attached), which we understand will be included under Item 4.01 of Form 8-K which will be filed with the Securities and Exchange Commission on July 11, 2022. We agree with the statements concerning our Firm contained therein. V

Joint Filing Agreement

Exhibit 99.8 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including any and all amendments thereto, the “Schedule 13D”) relating to the common stock, $0.001 par value per share, of MedAvail Holdings, Inc

MDVL / Medavail Holdings Inc / Redmile Group, LLC - SC 13D/A Activist Investment

UNITED STATES SECURITIES & EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* MedAvail Holdings, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 58406B103 (CUSIP Number) Redmile Group, LLC Attn: Jennifer Ciresi One Letterman Drive, Bldg D, Ste D3-300 San Francisco, CA 94129 (415) 489-998

Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2022 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36533 90-0772394 (State or other jurisdiction of incorporation) (Commission Fi

Registration Rights Agreement, dated as of March 30, 2022

EX-10.2 3 exhibit102-registrationrig.htm EX-10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into effective as of March 30, 2022, by and between MedAvail Holdings, Inc., a Delaware corporation (the “Company”) and each “Purchaser” named in the Purchase Agreement (as defined below) (collectively, the “Purchasers”). Capitalized terms used he

Securities Purchase Agreement, dated as of March 30, 2022

SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is made and entered into as of March 30, 2022 (the ?Effective Date?) by and among MedAvail Holdings, Inc.

Form of Warrant

EX-10.3 4 exhibit103-formofwarrant1.htm EX-10.3 THE OFFER AND SALE OF THESE SECURITIES AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED, ASSIGNED OR OTHERWISE DISPOSED OF (I) IN THE ABSENCE

MedAvail Holdings, Inc. 56,470,579 Shares of Common Stock

PROSPECTUS Filed Pursuant to Rule 424(b)(3) Registration No. 333-265402 MedAvail Holdings, Inc. 56,470,579 Shares of Common Stock This prospectus relates to the disposition, from time to time, by the selling stockholders identified in this prospectus under the caption ?Selling Stockholders? on page 9 of up to 56,470,579 shares of our common stock, including shares issuable upon the exercise of war

June 22, 2022

CORRESP 1 filename1.htm June 22, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Janice Adeloye Re: MedAvail Holdings, Inc. Registration Statement on Form S-3 Filed June 3, 2022 File No. 333-265402 Acceleration Request Requested Date: June 24, 2022 Requested Time: 4:30 p.m. (Eastern Time) Ladies and Gentlem

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2022 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36533 90-0772394 (State or other jurisdiction of incorporation) (Commission F

Amended and Restated Certificate of Incorporation of MedAvail Holdings, Inc.

EX-3.1 2 exhibit31-amendedandrestat.htm EX-3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF MEDAVAIL HOLDINGS, INC. MedAvail Holdings, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), does hereby certify as follows: A.The present name of the Corporation is MedAvail Holdings, Inc., and the original Certificate of Incorporation of the Co

As filed with the Securities and Exchange Commission on June 3, 2022

As filed with the Securities and Exchange Commission on June 3, 2022 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) MedAvail Holdings, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36533 MEDAVAIL H

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36533 90-0772394 (State or other jurisdiction of incorporation) (Commission Fi

Corporate Presentation 2 MedAvail Holdings, Inc. (“MedAvail”) cautions you that the statements in this presentation that are not a description of historical fact are forward- looking statements which may be identified by use of the words such as “ant

mdvlinvestorxpresentati Corporate Presentation 2 MedAvail Holdings, Inc. (“MedAvail”) cautions you that the statements in this presentation that are not a description of historical fact are forward- looking statements which may be identified by use of the words such as “anticipate,” “believe,” “expand,” “expect,” “grow,” “intend,” “opportunity,” “plan,” “potential,” “project”, “target” and “will”

MedAvail Reports First Quarter 2022 Financial Results

Exhibit 99.1 MedAvail Reports First Quarter 2022 Financial Results MISSISSAUGA, Ontario and PHOENIX, Ariz. ? May 12, 2022 ? MedAvail Holdings, Inc. (Nasdaq: MDVL) (?MedAvail?) a technology-enabled pharmacy company, today reported financial results for the three months ended March 31, 2022. ?I am proud of our team?s strong start to the year. We delivered robust sales growth in the first quarter and

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

DEFA14A 1 defa14ato2022proxystatement.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

DEF 14A 1 defproxystatement2022.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted b

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

PRE 14A 1 proxystatement2022.htm PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by R

As filed with the Securities and Exchange Commission on April 8, 2022

As filed with the Securities and Exchange Commission on April 8, 2022 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) MedAvail Holdings, Inc.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2022 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36533 90-0772394 (State or other jurisdiction of incorporation) (Commission F

MedAvail Holdings, Inc. 2022 Inducement Equity Incentive Plan and related forms of stock option and restricted stock unit agreements.

MEDAVAIL HOLDINGS, INC. 2022 INDUCEMENT EQUITY INCENTIVE PLAN 1.Purposes of the Plan; Award Types. (a)Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals entering into employment with the Company or any Parent or Subsidiary of the Company. The Plan permi

MDVL / Medavail Holdings Inc / Redmile Group, LLC - SC 13D/A Activist Investment

UNITED STATES SECURITIES & EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* MedAvail Holdings, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 58406B103 (CUSIP Number) Redmile Group, LLC Jeremy C. Green One Letterman Drive, Bldg D, Ste D3-300 San Francisco, CA 94129 Attention: Legal De

MDVL / Medavail Holdings Inc / Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* MedAvail Holdings, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 58406B103 (CUSIP Number) Fan Yu Unit 3002-3004, 30th Floor Gloucester Tower, The Landmark 15 Queen?s Road Central Hong Kong +852 31219699 (Name, Addres

Joint Filing Agreement, dated as of April 6, 2022, by and among Redmile Group, LLC, Jeremy C. Green, Redmile Capital Fund, L.P., and RedCo II Master Fund, L.P.

EX-99.4 2 tm2211784d3ex99-4.htm EXHIBIT 99.4 Exhibit 99.4 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including any and all amendments thereto, the “Schedule 13D”) relating to the common stock, $0.001 p

Registration Rights Agreement, dated as of March 30, 2022.

EX-10.2 3 exhibit102-registrationrig.htm EX-10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into effective as of March 30, 2022, by and between MedAvail Holdings, Inc., a Delaware corporation (the “Company”) and each “Purchaser” named in the Purchase Agreement (as defined below) (collectively, the “Purchasers”). Capitalized terms used he

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2022 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36533 90-0772394 (State or other jurisdiction of incorporation) (Commission

MedAvail Announces Pricing of $50 Million Private Placement

Exhibit 99.2 MedAvail Announces Pricing of $50 Million Private Placement Mississauga, Ontario and Phoenix, AZ?March 31, 2022? (Nasdaq: MDVL)? MedAvail Holdings, Inc. (?MedAvail?), a technology-enabled retail pharmacy company, today announced it has entered into a definitive securities purchase agreement for the sale of common stock and warrants to purchase common stock in a private placement with

MedAvail Announces First Closing of Private Placement

Exhibit 99.3 MedAvail Announces First Closing of Private Placement Mississauga, Ontario and Phoenix, AZ?April 4, 2022? (Nasdaq: MDVL)? MedAvail Holdings, Inc. (?MedAvail?), a technology-enabled retail pharmacy company, today announced the first closing of a private placement for the sale of approximately 37.6 million shares of common stock at an offering price of $1.0625 per share, together with t

Form of Warrant

THE OFFER AND SALE OF THESE SECURITIES AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), OR ANY APPLICABLE STATE SECURITIES LAWS.

Corporate Presentation 2 MedAvail Holdings, Inc. (“MedAvail”) cautions you that the statements in this presentation that are not a description of historical fact are forward- looking statements which may be identified by use of the words such as “ant

Corporate Presentation 2 MedAvail Holdings, Inc. (?MedAvail?) cautions you that the statements in this presentation that are not a description of historical fact are forward- looking statements which may be identified by use of the words such as ?anticipate,? ?believe,? ?expand,? ?expect,? ?grow,? ?intend,? ?opportunity,? ?plan,? ?potential,? ?project?, ?target? and ?will? among others. These forw

2022 by and among the Registrant and the Purchasers.

SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is made and entered into as of March 30, 2022 (the ?Effective Date?) by and among MedAvail Holdings, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36533 MEDAVAIL HOLDINGS, INC. (Exac

MedAvail Reports Fourth Quarter and Full Year 2021 Financial Results

Exhibit 99.1 MedAvail Reports Fourth Quarter and Full Year 2021 Financial Results MISSISSAUGA, Ontario and PHOENIX, Ariz. ? March 24, 2022 ? MedAvail Holdings, Inc. (Nasdaq: MDVL) (?MedAvail?) a technology-enabled pharmacy company, today reported financial results for the three months and full year ended December 31, 2021. ?I am excited to have joined MedAvail at a pivotal time when I believe that

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2022 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-53298 90-0772394 (State or other jurisdiction of incorporation) (Commission

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2022 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-53298 90-0772394 (State or other jurisdiction of incorporation) (Commission

MedAvail To Report 2021 Fourth Quarter and Full Year Financial Results on March 24, 2022

Exhibit 99.1 MedAvail To Report 2021 Fourth Quarter and Full Year Financial Results on March 24, 2022 MISSISSAUGA, Ontario and PHOENIX, Ariz. ? March 10, 2022 ? MedAvail Holdings, Inc. (Nasdaq: MDVL) (?MedAvail?) a technology-enabled pharmacy company, today announced it will report financial results for the full year and fourth quarter of 2021 on Thursday, March 24, 2022, after market close. MedAv

Change of Control and Severance Agreement between the Company and Steven Hess

MEDAVAIL TECHNOLOGIES (US) INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control and Severance Agreement (the ?Agreement?) is made by and between MedAvail Technologies (US) Inc., a Delaware corporation (the ?Company?), and Steven B. Hess (?Executive?), effective as of the Effective Date, as defined in Section 7 below. This Agreement provides certain protections to Executive in conn

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2022 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-53298 90-0772394 (State or other jurisdiction of incorporation) (Commissi

MedAvail Strengthens Leadership Team

Exhibit 99.1 MedAvail Strengthens Leadership Team MISSISSAUGA, Ontario and PHOENIX, Ariz. ? February 22, 2022 ? MedAvail Holdings, Inc. (Nasdaq: MDVL) (?MedAvail?) a technology-enabled pharmacy company, today announced the appointment of industry leaders Steven Hess to Executive Vice President, General Manager, of SpotRx and Bob McClune to Senior Vice President of Data and Analytics. ?We are pleas

Offer Letter between the Company and Steven Hess

PRIVATE AND CONFIDENTIAL Steven B. Hess Dear Steven, Re: Offer of Employment We at MedAvail Technologies (US), Inc. (?MedAvail? or the ?Company?) believe that we are able to provide you with exciting and challenging career opportunities as part of our team. MedAvail is pleased to extend to you an offer of employment on the terms and conditions outlined below. 1.Title. You will be employed as Execu

MDVL / Medavail Holdings Inc / ADAGE CAPITAL PARTNERS GP, L.L.C. Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* MedAvail Holdings, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 58406B103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursua

MDVL / Medavail Holdings Inc / Redmile Group, LLC - SC 13D/A Activist Investment

UNITED STATES SECURITIES & EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* MedAvail Holdings, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 58406B103 (CUSIP Number) Redmile Group, LLC Jeremy C. Green One Letterman Drive, Bldg D, Ste D3-300 San Francisco, CA 94129 Attention: Legal De

Joint Filing Agreement, dated as of January 14, 2022, by and among Redmile Group, LLC, Jeremy C. Green, Redmile Capital Fund, L.P., Redmile Capital Offshore II Master Fund, Ltd., Redmile Strategic Master Fund, LP, Redmile Private Investments I, L.P., and RedCo I, L.P.

Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including any and all amendments thereto, the ?Schedule 13D?) relating to the common stock, $0.001 par value per share, of MedAvail Holdings, Inc

Transition Services Agreement between the Company and Ed Kilroy

EX-10.3 4 exhibit1038-k11122.htm EX-10.3 Exhibit 10.3 January 4th, 2022 WITHOUT PREJUDICE Delivered via email Ed Kilroy Dear Mr. Kilroy: Re: Notice of Termination of Employment This letter will confirm our discussions today at which time we advised you that your employment with Medavail will be terminated without just cause. With a view to providing you with some assistance as you prepare to trans

Offer Letter between the Company and Mark Doerr

EX-10.1 2 exhibit101-8xk11122.htm EX-10.1 Exhibit 10.1 PRIVATE AND CONFIDENTIAL Mark Doerr Dear Mark, Re: Offer of Employment We at MedAvail Technologies (US), Inc. (“MedAvail” or the “Company”) believe that we are able to provide you with exciting and challenging career opportunities as part of our team. MedAvail is pleased to extend to you an offer of employment on the terms and conditions outli

Change of Control and Severance Agreement between the Company and Mark Doerr

EX-10.2 3 exhibit1028-k11121.htm EX-10.2 Exhibit 10.2 MEDAVAIL TECHNOLOGIES (US) INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control and Severance Agreement (the “Agreement”) is made by and between MedAvail Technologies (US) Inc., a Delaware corporation (the “Company”), and Mark Doerr (“Executive”), effective as of the Effective Date, as defined in Section 7 below. This Agreement

MedAvail Announces Changes to Executive Management and Board of Directors; Preliminary Fourth Quarter and FY 2021 Results

EX-99.1 5 exhibit991-8xk11122.htm EX-99.1 Exhibit 99.1 MedAvail Announces Changes to Executive Management and Board of Directors; Preliminary Fourth Quarter and FY 2021 Results MISSISSAUGA, Ontario and PHOENIX, Ariz. –January 11, 2022– MedAvail Holdings, Inc. (Nasdaq: MDVL) (“MedAvail”), a technology-enabled pharmacy company, today announced that Mark Doerr, RPh, has joined the company as chief ex

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2022 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-53298 90-0772394 (State or other jurisdiction of incorporation) (Commissio

MDVL / Medavail Holdings Inc / Redmile Group, LLC - SC 13D/A Activist Investment

UNITED STATES SECURITIES & EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* MedAvail Holdings, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 58406B103 (CUSIP Number) Redmile Group, LLC Jeremy C. Green One Letterman Drive, Bldg D, Ste D3-300 San Francisco, CA 94129 Attention: Legal De

Joint Filing Agreement, dated as of November 29, 2021, by and among Redmile Group, LLC, Jeremy C. Green, Redmile Capital Fund, L.P., Redmile Capital Offshore II Master Fund, Ltd., Redmile Strategic Master Fund, LP, Redmile Private Investments I, L.P., and RedCo I, L.P..

Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including any and all amendments thereto, the ?Schedule 13D?) relating to the common stock, $0.001 par value per share, of MedAvail Holdings, Inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36533 MEDAVA

Corporate Presentation 2 Safe Harbor Statements Forward-Looking Statements. MedAvail, Inc. (“MedAvail”) cautions you that the statements in this presentation that are not a description of historical fact are forward- looking statements which may be i

Corporate Presentation 2 Safe Harbor Statements Forward-Looking Statements. MedAvail, Inc. (?MedAvail?) cautions you that the statements in this presentation that are not a description of historical fact are forward- looking statements which may be identified by use of the words such as ?anticipate,? ?believe,? ?expand,? ?expect,? ?grow,? ?intend,? ?opportunity,? ?plan,? ?potential,? ?project?, ?t

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2021 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-53298 90-0772394 (State or other jurisdiction of incorporation) (Commissio

MedAvail Reports Third Quarter 2021 Financial Results

Exhibit 99.1 MedAvail Reports Third Quarter 2021 Financial Results MISSISSAUGA, Ontario and PHOENIX, Ariz. ? November 8, 2021 ? MedAvail Holdings, Inc. (Nasdaq: MDVL) (?MedAvail?) a technology-enabled pharmacy company, today reported financial results for the three months ended September 30, 2021. ?We are encouraged by our third quarter results, highlighted by our recent partnerships to broaden ou

MedAvail to Report 2021 Third Quarter Financial Results on November 8, 2021

Exhibit 99.1 MedAvail to Report 2021 Third Quarter Financial Results on November 8, 2021 MISSISSAUGA, Ontario and PHOENIX, Ariz. ? October 25, 2021 ? MedAvail Holdings, Inc. (Nasdaq: MDVL) (?MedAvail?) a technology-enabled pharmacy company, today announced it will report financial results for the third quarter 2021 on Monday, November 8, 2021, after market close. Company management will be webcast

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2021 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-53298 90-0772394 (State or other jurisdiction of incorporation) (Commissio

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 24, 2021 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-53298 90-0772394 (State or other jurisdiction of incorporation) (Commiss

MedAvail Appoints Ramona Seabaugh as Chief Financial Officer

MedAvail Appoints Ramona Seabaugh as Chief Financial Officer MISSISSAUGA, Ontario and PHOENIX, Ariz.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2021 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-53298 90-0772394 (State or other jurisdiction of incorporation) (Commiss

Offer Letter, dated August 12, 2021, by and between MedAvail Technologies (US), Inc. and Ramona Seabaugh

August 11, 2021 PRIVATE AND CONFIDENTIAL Ramona Seabaugh Dear Ramona, Re: Offer of Employment We at MedAvail Technologies (US), Inc.

Change in Control and Severance Agreement, dated August 31, 2021, by and between MedAvail Technologies (US), Inc. and Ramona Seabaugh

EX-10.2 3 medavail-changeincontrolan.htm EX-10.2 MEDAVAIL TECHNOLOGIES (US) INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control and Severance Agreement (the “Agreement”) is made by and between MedAvail Technologies (US) Inc., a Delaware corporation (the “Company”), and Ramona Seabaugh (“Executive”), effective as of the Effective Date, as defined in Section 7 below. This Agreement

Corporate Presentation 2 Safe Harbor Statements Forward-Looking Statements. MedAvail, Inc. (“MedAvail”) cautions you that the statements in this presentation that are not a description of historical fact are forward- looking statements which may be i

Corporate Presentation 2 Safe Harbor Statements Forward-Looking Statements. MedAvail, Inc. (?MedAvail?) cautions you that the statements in this presentation that are not a description of historical fact are forward- looking statements which may be identified by use of the words such as ?anticipate,? ?believe,? ?expand,? ?expect,? ?grow,? ?intend,? ?opportunity,? ?plan,? ?potential,? ?project?, ?t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2021 MEDAVAIL HOLDI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2021 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-53298 90-0772394 (State or other jurisdiction of incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36533 MEDAVAIL HO

MedAvail Reports Second Quarter 2021 Financial Results

Exhibit 99.1 MedAvail Reports Second Quarter 2021 Financial Results MISSISSAUGA, Ontario and PHOENIX, Ariz. ? August 11, 2021 ? MedAvail Holdings, Inc. (Nasdaq: MDVL) (?MedAvail?) a technology-enabled pharmacy company, today reported financial results for the three months ended June 30, 2021. ?We are pleased with our second quarter results which reflect continued momentum, as our sales grew 118% o

SpotRx Joins Zipdrug’s Pharmacy Network The partnership enables health plan members to be connected to SpotRx

EX-99.1 2 exhibit991-8xk81121zipdrug.htm EX-99.1 Exhibit 99.1 SpotRx Joins Zipdrug’s Pharmacy Network The partnership enables health plan members to be connected to SpotRx MISSISSAUGA, Ontario and PHOENIX, Ariz. – August 11, 2021 – MedAvail Holdings, Inc. (Nasdaq: MDVL) (“MedAvail”), a technology-enabled retail pharmacy company, today announced that SpotRx has been selected as a Partner Pharmacy o

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2021 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-53298 90-0772394 (State or other jurisdiction of incorporation) (Commission

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2021 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-53298 90-0772394 (State or other jurisdiction of incorporation) (Commission

MedAvail to Report 2021 Second Quarter Financial Results on August 11, 2021

Exhibit 99.1 MedAvail to Report 2021 Second Quarter Financial Results on August 11, 2021 MISSISSAUGA, Ontario and PHOENIX, Ariz. ? July 28, 2021 ? MedAvail Holdings, Inc. (Nasdaq: MDVL) (?MedAvail?) a technology-enabled pharmacy company, today announced it will report financial results for the second quarter 2021 on Wednesday, August 11, 2021 after market close. Company management will be webcasti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2021 MEDAVAIL HOLDINGS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2021 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-53298 90-0772394 (State or other jurisdiction of incorporation) (Commission F

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2021 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-53298 90-0772394 (State or other jurisdiction of incorporation) (Commission F

MedAvail Announces CFO Transition

MedAvail Announces CFO Transition MISSISSAUGA, Ontario and PHOENIX, Ariz. ? June 14, 2021 ? MedAvail Holdings, Inc. (Nasdaq: MDVL) (?MedAvail? or the ?Company?) a technology-enabled pharmacy company, today announced that Ryan Ferguson has informed the Company of his intention to step down as Chief Financial Officer to pursue other opportunities effective July 31, 2021. Mr. Ferguson has agreed to t

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2021 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-53298 90-0772394 (State or other jurisdiction of incorporation) (Commission F

Loan and Security Agreement Dated June 7, 2021

LOAN AND SECURITY AGREEMENT This LOAN AND SECURITY AGREEMENT (this ?Agreement?) is dated as of the Effective Date among (a) SILICON VALLEY BANK, a California corporation and an authorized foreign bank under the Bank Act (Canada) (?SVB?), in its capacity as administrative agent and collateral agent (?Agent?), (b) SVB, as a lender, (c) SVB INNOVATION CREDIT FUND VIII, L.

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2021 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-53298 90-0772394 (State or other jurisdiction of incorporation) (Commission Fi

Corporate Presentation 2 Safe Harbor Statements Forward-Looking Statements. MedAvail, Inc. (“MedAvail”) cautions you that the statements in this presentation that are not a description of historical fact are forward- looking statements which may be i

Corporate Presentation 2 Safe Harbor Statements Forward-Looking Statements. MedAvail, Inc. (?MedAvail?) cautions you that the statements in this presentation that are not a description of historical fact are forward- looking statements which may be identified by use of the words such as ?anticipate,? ?believe,? ?expand,? ?expect,? ?grow,? ?intend,? ?opportunity,? ?plan,? ?potential,? ?project?, ?t

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2021 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-53298 90-0772394 (State or other jurisdiction of incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36533 MEDAVAIL H

15,193,972 Shares of Common Stock by the Selling Stockholders

Filed Pursuant to Rule 424(b)(3) Registration No. 333-255347 PROSPECTUS 15,193,972 Shares of Common Stock by the Selling Stockholders This prospectus relates to the resale from time to time by the Selling Stockholders named in this prospectus (together with their respective donees, transferees or other successors in interest, referred to as the Selling Stockholders) of up to 15,193,972 shares of o

As filed with the Securities and Exchange Commission on May 12, 2021

As filed with the Securities and Exchange Commission on May 12, 2021 Registration No.

May 13, 2021

May 13, 2021 Via EDGAR Division of Corporation Finance U.S. Securities & Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Jeffrey Gabor Re: MedAvail Holdings, Inc. Registration Statement on Form S-1 Filed May 13, 2021 File No. 333-255347 Acceleration Request Requested Date: May 14, 2021 Requested Time: 4:05 P.M. Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 under

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2021 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-53298 90-0772394 (State or other jurisdiction of incorporation) (Commission Fi

MedAvail Reports First Quarter 2021 Financial Results

Exhibit 99.1 MedAvail Reports First Quarter 2021 Financial Results MISSISSAUGA, Ontario and PHOENIX, Ariz. ? May 12, 2021 ? MedAvail Holdings, Inc. (Nasdaq: MDVL) (?MedAvail?) a technology-enabled pharmacy company, today reported financial results for the three months ended March 31, 2021. ?Our first quarter results illustrate a strong start to the year, as our revenue grew over 30% on a sequentia

May 12, 2021

May 12, 2021 Via EDGAR and Courier United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F St NE Washington, D.

- DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a6(e)(2)) ? Definitive Proxy Statem

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2021 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-53298 90-0772394 (State or other jurisdiction of incorporation) (Commission

MedAvail to Report 2021 First Quarter Financial Results on May 12, 2021

Exhibit 99.1 MedAvail to Report 2021 First Quarter Financial Results on May 12, 2021 MISSISSAUGA, Ontario and PHOENIX, Ariz. ? April 28, 2021 ? MedAvail Holdings, Inc. (Nasdaq: MDVL) (?MedAvail?) a technology-enabled pharmacy company, today announced it will report financial results for the first quarter 2021 on Wednesday, May 12, 2021 after market close. Company management will be webcasting a co

- S-8

As filed with the Securities and Exchange Commission on April 19, 2021 Registration No.

Power of Attorney

As filed with the Securities and Exchange Commission on April 19, 2021 Registration No.

Exhibit 4.1

Exhibit 4.1 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The authorized capital stock of MedAvail Holdings, Inc., consists of 110,000,000 shares of common stock, par value $0.001 per share, and 10,000,000 shares of convertible preferred stock, par value $0.001 per share. We have one class of securities registered under Section

Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36533 MEDAVAIL HOLDINGS, INC. (Exac

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2021 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-53298 90-0772394 (State or other jurisdiction of incorporation) (Commission

MedAvail Reports Fourth Quarter and Full Year 2020 Financial Results

Exhibit 99.1 MedAvail Reports Fourth Quarter and Full Year 2020 Financial Results MISSISSAUGA, Ontario and PHOENIX, Ariz. – March 30, 2021 – MedAvail Holdings, Inc. (Nasdaq: MDVL) (“MedAvail”) a technology-enabled pharmacy company, today reported financial results for the three months and full year ended December 31, 2020. MedAvail drives best-in-class medication adherence by embedding its pharmac

Corporate Presentation 2 Safe Harbor Statements Forward-Looking Statements. MedAvail, Inc. (“MedAvail”) cautions you that the statements in this presentation that are not a description of historical fact are forward-looking statements which may be id

Corporate Presentation 2 Safe Harbor Statements Forward-Looking Statements. MedAvail, Inc. (?MedAvail?) cautions you that the statements in this presentation that are not a description of historical fact are forward-looking statements which may be identified by use of the words such as ?anticipate,? ?believe,? ?expand,? ?expect,? ?grow,? ?intend,? ?opportunity,? ?plan,? ?potential,? ?project?, ?ta

MedAvail Announces Preliminary Fourth Quarter and Full Year 2020 Results

MedAvail Announces Preliminary Fourth Quarter and Full Year 2020 Results MISSISSAUGA, Ontario and PHOENIX, Ariz.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2021 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-53298 90-0772394 (State or other jurisdiction of incorporation) (Commissi

Joint Filing Statement Statement Pursuant to Rule 13d-1(k)(1)

Exhibit 1 Joint Filing Statement Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to file a joint statement on Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the Common Stock, Par Value $0.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* MEDAVAIL HOLDINGS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) (CUSIP Number) Decemb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

- FORM 144

UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0101 Washington, D.

- S-8

As filed with the Securities and Exchange Commission on December 1, 2020 Registration No.

MDVL / MedAvail Holdings, Inc. / Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. - SC 13D Activist Investment

SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* MedAvail Holdings, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 58406B103 (CUSIP Number) Fan Yu Unit 3002-3004, 30th Floor Gloucester Tower, The Landmark 15 Queen’s Road Central Hong Kong +852 31219699 (Name,

Joint Filing Agreement.

EX-1 Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13D.

Joint Filing Agreement, dated as of November 27, 2020, by and among Redmile Group, LLC, Jeremy C. Green, Redmile Capital Fund, L.P., Redmile Capital Offshore II Master Fund, Ltd., Redmile Strategic Master Fund, L.P., Redmile Private Investments I, L.P. and RedCo I, L.P.

Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including any and all amendments thereto, the “Schedule 13D”) relating to the common stock, $0.001 par value per share, of MedAvail Holdings, Inc

MDVL / MedAvail Holdings, Inc. / ADAGE CAPITAL PARTNERS GP, L.L.C. - MEDAVAIL HOLDINGS, INC. Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* MedAvail Holdings, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 58406B103 (CUSIP Number) November 17, 2020 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant t

MDVL / MedAvail Holdings, Inc. / Redmile Group, LLC - SC 13D Activist Investment

UNITED STATES SECURITIES & EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* MedAvail Holdings, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 58406B103 (CUSIP Number) Redmile Group, LLC Jeremy C. Green One Letterman Drive, Bldg D, Ste D3-300 San Francisco, CA 94129 Attention: Legal Dep

Letter to the Securities and Exchange Commission from WithumSmith+Brown, PC, dated November 25, 2020

Exhibit 16.1 November 25, 2020 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 We have been furnished with a copy of the disclosures in Item 4.01 of Form 8-K for the event that occurred on November 25, 2020, to be filed by our former client, MedAvail Holdings, Inc. (f/k/a MYOS RENS Technology Inc.). We agree with the statements made in response to that Item insofar as th

MDVL / MedAvail Holdings, Inc. / PURA VIDA INVESTMENTS, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* MEDAVAIL HOLDINGS, INC.

Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 25, 2020 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-53298 90-0772394 (State or other jurisdiction of incorporation) (Commissi

Joint Filing Statement Statement Pursuant to Rule 13d-1(k)(1)

Exhibit 1 Joint Filing Statement Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to file a joint statement on Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the Common Stock, Par Value $0.

Amended and Restated Bylaws of the Registrant

EX-3.2 3 exhibit32-8xk111820.htm EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF MEDAVAIL HOLDINGS, INC. (amended and restated on November 18, 2020) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES 2 2.5 NOTICE OF

FINANCIAL STATEMENTS

EX-99.1 12 exhibit991-8xk111820.htm EX-99.1 Exhibit 99.1 FINANCIAL STATEMENTS Report of Independent Auditors To the Board of Directors of MedAvail, Inc. We have audited the accompanying consolidated financial statements of MedAvail, Inc. and its subsidiaries, which comprise the consolidated balance sheets as of December 31, 2019 and 2018, and the related consolidated statements of operations, comp

Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Submission of Matters to a Vote of Security Holders - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2020 MEDAVAIL HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 000-53298 90-0772394 (State or other jurisdiction of incorporation or organiz

MedAvail and MYOS RENS Technology Announce Closing of Business Combination MedAvail, Inc. Set to Trade on NASDAQ Under Ticker Symbol “MDVL”

Exhibit 99.2 MedAvail and MYOS RENS Technology Announce Closing of Business Combination MedAvail, Inc. Set to Trade on NASDAQ Under Ticker Symbol “MDVL” MISSISSAUGA, Ontario and CEDAR KNOLLS, N.J. – November 18, 2020 – MedAvail, Inc. (“MedAvail”), a leading technology-enabled pharmacy organization that embeds pharmacy services directly into clinics and other points of care through its proprietary

MedAvail Holdings, Inc. 2020 Employee Stock Purchase Plan

EX-10.12 7 exhibit1012-8xk111820.htm EX-10.12 Exhibit 10.12 MEDAVAIL HOLDINGS, INC. 2020 EMPLOYEE STOCK PURCHASE PLAN 1.Purpose. The purpose of the Plan is to provide employees of the Company and its Designated Companies with an opportunity to purchase Common Stock through accumulated Contributions. The Company intends for the Plan to have two components: a component that is intended to qualify as

MedAvail, Inc. 2012 Equity Incentive Plan, as amended, and related form agreements

Exhibit 10.13 MEDAVAIL,INC. STOCK OPTION PLAN ADOPTED AS OF JUNE 10, 2012 AMENDED AS OF DECEMBER 19, 2013 STOCK OPTION PLAN The purpose of this Plan is to advance the interests of the Company and its Subsidiaries (as defined herein) by: (i) providing Eligible Persons (as defined herein) with additional incentives; (ii) encouraging share ownership by Eligible Persons; (iii) increasing the proprieta

Form of Common Stock Purchase Warrant issued by the Registrant to H.C. Wainwright & Co., LLC or its affiliates

Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

MedAvail Holdings, Inc. 2020 Equity Incentive Plan and related form agreements

EX-10.11 6 exhibit1011-8xk111820.htm EX-10.11 Exhibit 10.11 MEDAVAIL HOLDINGS, INC. 2020 EQUITY INCENTIVE PLAN 1.Purposes of the Plan; Award Types. (a)Purposes of the Plan. The purposes of this Plan are to attract and retain personnel for positions with the Company Group, to provide additional incentive to Employees, Directors, and Consultants, and to promote the success of the Company’s business.

MEDAVAIL MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

EX-99.3 14 exhibit993-8xk111820.htm EX-99.3 Exhibit 99.3 MEDAVAIL MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following discussion and analysis of MedAvail’s financial condition and results of operations together with the section entitled “Selected Historical and Unaudited Pro Forma Condensed Combined Financial Data — Selected Historica

Form of Indemnification Agreement between the Registrant and each director and executive officer of the Registrant

Exhibit 10.15 MEDAVAIL HOLDINGS, INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement (this “Agreement”) is dated as of [●] and is between MedAvail Holdings, Inc., a Delaware corporation (the “Company”), and [●] (“Indemnitee”). RECITALS WHEREAS, Indemnitee’s service to the Company substantially benefits the Company. WHEREAS, individuals are reluctant to serve as directors or officers of c

MedAvail, Inc. 2018 Equity Incentive Plan and related form agreements

Exhibit 10.14 MEDAVAIL, INC. 2018 EQUITY INCENTIVE PLAN 1.Purposes of the Plan. The purposes of this Plan are: •to attract and retain the best available personnel for positions of substantial responsibility, •to provide additional incentive to Employees, Directors and Consultants, and •to promote the success of the Company’s business. The Plan permits the grant of Incentive Stock Options and Nonst

Amended and Restated Certificate of Incorporation of the Registrant

EX-3.1 2 exhibit31-86111820.htm EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF MYOS RENS TECHNOLOGY INC. MYOS RENS Technology Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), does hereby certify as follows: A.The present name of the Corporation is MYOS RENS Technology Inc., and the original Certificate of Incorporation

Form of Common Stock Purchase Warrant issued by MedAvail, Inc.

Exhibit 4.1 THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATE. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS IN ACCORDANCE WITH APPLICABLE REGISTRATION REQUIREMENTS

Subsidiaries of the Registrant

Exhibit 21.1 Subsidiaries of MedAvail Holdings, Inc. Entity Name State or Jurisdiction of Incorporation MedAvail, Inc. State of Delaware MedAvail Technologies Inc. Ontario Canada MedAvail Technologies (US) Inc. State of Delaware MedAvail Pharmacy Inc. (d/b/a SpotRx Pharmacy) State of Arizona

Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Other Events - CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2020 MYOS RENS TECHNOLOGY INC. (Exact name of registrant as specified in its charter) Nevada 000-53298 90-0772394 (State or other jurisdiction of incorporation or organiz

MYOS RENS TECHNOLOGY BOARD OF DIRECTORS approved the Reverse Stock Split ratio of one new share for every 12 shares of Common Stock outstanding

EX-99.1 2 ea130024ex99-1myosrenstech.htm PRESS RELEASE Exhibit 99.1 MYOS RENS TECHNOLOGY BOARD OF DIRECTORS approved the Reverse Stock Split ratio of one new share for every 12 shares of Common Stock outstanding CEDAR KNOLLS, N.J., November 17, 2020 /PRNewswire/ - MYOS RENS Technology Inc. ("MYOS" or the “Company") (NASDAQ: MYOS) As previously announced, on June 30, 2020, MYOS RENS Technology, Inc

MYOS RENS TECHNOLOGY BOARD OF DIRECTORS approved the Reverse Stock Split ratio of one new share for every 12 shares of Common Stock outstanding

Exhibit 99.1 MYOS RENS TECHNOLOGY BOARD OF DIRECTORS approved the Reverse Stock Split ratio of one new share for every 12 shares of Common Stock outstanding CEDAR KNOLLS, N.J., November 17, 2020 /PRNewswire/ - MYOS RENS Technology Inc. ("MYOS" or the “Company") (NASDAQ: MYOS) As previously announced, on June 30, 2020, MYOS RENS Technology, Inc., a Nevada corporation (“MYOS”), and MedAvail, Inc., a

Merger Prospectus - CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2020 MYOS RENS TECHNOLOGY INC. (Exact name of registrant as specified in its charter) Nevada 000-53298 90-0772394 (State or other jurisdiction of incorporation or organiz

MYOS RENS Technology Announces anticipated exchange ratio, immediately after the completion of the Merger

Exhibit 99.1 Investor Relations: MYOS RENS Technology Joanne Goodford Phone: 973-509-0444 Email: [email protected] MYOS RENS Technology Announces anticipated exchange ratio, immediately after the completion of the Merger CEDAR KNOLLS, N.J., November 12, 2020 /PRNewswire/ - MYOS RENS Technology Inc. ("MYOS" or the “Company") (NASDAQ: MYOS) As previously announced, on June 30, 2020, MYOS RENS T

Financial Statements and Exhibits, Other Events - CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2020 MYOS RENS TECHNOLOGY INC. (Exact name of registrant as specified in its charter) Nevada 000-53298 90-0772394 (State or other jurisdiction of incorporation or organiz

MYOS RENS Technology Announces anticipated exchange ratio, immediately after the completion of the Merger

EX-99.1 2 ea129756ex99-1myosrens.htm PRESS RELEASE, DATED NOVEMBER 12, 2020. Exhibit 99.1 Investor Relations: MYOS RENS Technology Joanne Goodford Phone: 973-509-0444 Email: [email protected] MYOS RENS Technology Announces anticipated exchange ratio, immediately after the completion of the Merger CEDAR KNOLLS, N.J., November 12, 2020 /PRNewswire/ - MYOS RENS Technology Inc. ("MYOS" or the “Co

Merger Prospectus - CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2020 MYOS RENS TECHNOLOGY INC. (Exact name of registrant as specified in its charter) Nevada 000-53298 90-0772394 (State or other jurisdiction of incorporation or organiz

Other Events - CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2020 MYOS RENS TECHNOLOGY INC. (Exact name of registrant as specified in its charter) Nevada 000-53298 90-0772394 (State or other jurisdiction of incorporation or organiza

Merger Prospectus - CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2020 MYOS RENS TECHNOLOGY INC. (Exact name of registrant as specified in its charter) Nevada 000-53298 90-0772394 (State or other jurisdiction of incorporation or organiza

Quarterly Report - QUARTERLY REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-53298 MYOS RENS TECHNOL

stockholder UPDATE

Exhibit 99.1 stockholder UPDATE November 3, 2020 EXECUTIVE SUMMARY As you likely know, MedAvail, Inc. (“MedAvail”) and MYOS RENS Technology Inc. (“MYOS”) entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) on June 30, 2020, by and among MYOS, MedAvail, and Matrix Merger Sub, Inc., a newly-created wholly-owned subsidiary of MYOS (“Merger Sub”), pursuant to which

Financial Statements and Exhibits, Other Events - CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2020 MYOS RENS TECHNOLOGY INC. (Exact name of registrant as specified in its charter) Nevada 000-53298 90-0772394 (State or other jurisdiction of incorporation or organiza

stockholder UPDATE

EX-99.1 2 ea129313ex99-1myosrens.htm MEDAVAIL, INC. WRITTEN COMMUNICATION TO ITS SECURITY HOLDERS, DATED NOVEMBER 3, 2020 Exhibit 99.1 stockholder UPDATE November 3, 2020 EXECUTIVE SUMMARY As you likely know, MedAvail, Inc. (“MedAvail”) and MYOS RENS Technology Inc. (“MYOS”) entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) on June 30, 2020, by and among MYOS

Merger Prospectus - CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2020 MYOS RENS TECHNOLOGY INC. (Exact name of registrant as specified in its charter) Nevada 000-53298 90-0772394 (State or other jurisdiction of incorporation or organiza

Merger Prospectus - CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2020 MYOS RENS TECHNOLOGY INC. (Exact name of registrant as specified in its charter) Nevada 000-53298 90-0772394 (State or other jurisdiction of incorporation or organiza

Other Events - CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2020 MYOS RENS TECHNOLOGY INC. (Exact name of registrant as specified in its charter) Nevada 000-53298 90-0772394 (State or other jurisdiction of incorporation or organiza

PROPOSED MERGER YOUR VOTE IS VERY IMPORTANT

Filed Pursuant to Rule 424(b)(3) Registration No. 333-248566 PROPOSED MERGER YOUR VOTE IS VERY IMPORTANT To the Equity Holders of MYOS RENS Technology Inc., and MedAvail, Inc.: MYOS RENS Technology Inc., or MYOS, and MedAvail, Inc., or MedAvail, have entered into an Agreement and Plan of Merger and Reorganization, or the Merger Agreement, pursuant to which a wholly owned subsidiary of MYOS will me

MYOS RENS TECHNOLOGIES INC. 45 Horsehill Road, Suite 106 Cedar Knolls, NJ 07927 October 13, 2020

MYOS RENS TECHNOLOGIES INC. 45 Horsehill Road, Suite 106 Cedar Knolls, NJ 07927 October 13, 2020 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 Attention: Laura Crotty, Staff Attorney Re: MYOS RENS Technologies, Inc. Registration Statement on Form S-4 File No. 333-248566 ACCELERATION REQUEST Dear Ms. Crotty: Pursuant to Rule 46

Other Events - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 9, 2020 MYOS RENS TECHNOLOGY INC. (Exact name of registrant as specified in its charter) Nevada 000-53298 90-0772394 (State or other jurisdiction of incorporation) (Commission

Merger Prospectus - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 9, 2020 MYOS RENS TECHNOLOGY INC. (Exact name of registrant as specified in its charter) Nevada 000-53298 90-0772394 (State or other jurisdiction of incorporation) (Commission

Form of MYOS RENS Technology Inc. Proxy Card

EX-99.1 10 exhibit991-sx4a1xformo.htm EX-99.1 Exhibit 99.1

Amended and Restated Investors’ Rights Agreement by and among the Registrant, MedAvail, Inc., and certain stockholders, dated October 9, 2020

Exhibit 4.9 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT This AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is entered into as of , 2020 by and among MedAvail, Inc., a Delaware corporation (the “Company”), the Prior Holders, and certain persons and entities listed on Exhibit A attached hereto (collectively with the Prior Holders, the “Investors”), and upon delivery of a d

Consent of Ed Kilroy to serve as a director of MYOS RENS Technology Inc.

Exhibit 99.2 Consent of Prospective Director I, Ed Kilroy, in accordance with Rule 438 promulgated under the Securities Act of 1933, as amended, (the “Securities Act”), hereby consent to the following: •to serve as a director of MYOS RENS Technology Inc. (“MYOS”) if the transactions contemplated by that certain Agreement and Plan of Merger and Reorganization, dated as of June 30, 2020 (as it may b